Abstract | OBJECTIVE: METHODS: RESULTS: The morphology of the tumors in RU486 plus DDP group was significantly different as compared with that of the control group. In comparison with exclusive DDP treatment, combined treatment with RU486 and DDP resulted in significantly greater inhibition rates of the tumors (70.48% vs 21.55%, P < 0.01). GcS mRNA expression was lowered in both RU486 plus DDP and RU486 groups, especially in the former group, as compared with that in control group. CONCLUSION: At a non-toxic dose, RU486 may enhance the sensitivity of tumor cells to cisplatin in vivo, possibly through the mechanism of inhibiting GcS expression at the mRNA level.
|
Authors | Ying Liu, Li-li Wang, Yan Deng |
Journal | Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
(Di Yi Jun Yi Da Xue Xue Bao)
Vol. 23
Issue 3
Pg. 242-4
(Mar 2003)
ISSN: 1000-2588 [Print] China |
PMID | 12651241
(Publication Type: Journal Article)
|
Chemical References |
- Abortifacient Agents, Steroidal
- Mifepristone
- Cisplatin
|
Topics |
- Abortifacient Agents, Steroidal
(administration & dosage)
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cell Division
(drug effects)
- Cisplatin
(administration & dosage)
- Disease Models, Animal
- Drug Resistance, Neoplasm
- Drug Screening Assays, Antitumor
- Drug Synergism
- Female
- Humans
- Mice
- Mice, Nude
- Mifepristone
(administration & dosage)
- Neoplasm Transplantation
- Neoplasms, Experimental
(prevention & control)
- Ovarian Neoplasms
(pathology)
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
|